I. Rousalova (Prague, Czech Republic), D. Baldwin (Nottingham, United Kingdom)
Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib
H. Ge, S. Ni, X. Fang, N. Xu, Y. Liu, Y. Song, C. Bai (Shanghai, Nantong, China)
|   |
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
N. Koyama, S. Minesaki, S. Yamazaki, H. Utsugi, Y. Maeno, T. Okano, Y. Murayama, K. Kobayashi (Hidaka-shi, Japan)
| |
Improved results after preoperative concurrent chemotherapy and high dose radiation therapy in selected cases with stage III N2 lung cancer?
K. Athanassiadi, E. Balis, N. Alevizopoulos, D. Lioumpas, M.K. Konstantinidou, I. Ttofi, I. Mavromati, A. Psevdi, L. Comis, D. Violidaki, D. Rondogianni, I. Bellenis (Athens, Greece)
| |
Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic
J. Skrickova, K. Hejduk, Z. Bortlicek, M. Pesek, V. Kolek, L. Koubkova, P. Zatloukal, F. Salajka, M. Zemanova, D. Sixtova, J. Roubec, H. Coupkova (Brno, Plzen, Olomouc, Praha, Hradec Kralove, Ostrava, Czech Republic)
| |
Non-small cell lung carcinoma–advanced disease (NSCLC-AD): Effectiveness of subsequent therapeutic lines and predictive factors of poor outcome
L. Fernandes, I. Sanches, C. Ferreira, A. Figueiredo, F. Barata (Coimbra, Portugal)
| |
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
C. Ferreira, L. Fernandes, A. Figueiredo, F. Barata (Coimbra, Portugal)
| |
A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema
M. Morita, K. Hashimoto, A. Yamasaki, T. Igishi, E. Shimizu (Yonago, Japan)
| |
Management of chemotherapy-induced anemia in patients with lung cancer (LC): A comparative study of erythropoietic agents
A. Tiotiu, C. Clément-Duchêne, P. Vaillant, P. Barbier, D. Tiotiu, Y. Martinet (Nancy, France)
| |
Docetaxel-related peripheral neuropathy is a dose-dependent event; a retrospective study in a Greek population with NSCLC
A. Kavvadias, I. Gkiozos, P. Boulas, G. Tsoukalas, K. Syrigos (Athens, Greece)
| |
Is skin toxicity a predictive or prognostic factor in EGFR-inhibition as treatment of advanced NSCLC?
S. Rüdiger, C. Kropf-Sanchen, G. Schmid-Bindert, T. Wibmer, K. Stoiber, I. Blanta, W. Rottbauer, C. Schumann (Ulm, Mannheim, Germany)
| |
Anti-cancer therapy and monitoring plasma concentration of carboplatin in lung cancer patients receiving hemodialysis
Y. Sakamoto, A. Masunaga, R. Sato, S. Sakata, S. Saeki, J.I. Sasaki, K. Nishi, T. Hamada, H. Saito, H. Kohrogi (Kumamoto, Japan)
| |
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
M. Talebian Yazdi, N.M. Loof, J.T. Annema, C.J. Melief, P.S. Hiemstra, M.J.P. Welters, J. Oostendorp, S.H. van der Burg (Leiden, Netherlands)
| |
Do elderly lung cancer patients profit from radical mediastinal lymphadenectomy?
K. Athanassiadi, V. Karameri, I. Mavromati, I. Samiotis, M.K. Konstantinidou, D. Violidaki, D. Riga, D. Lioumpas, D. Rondogianni, I. Bellenis (Athens, Greece)
| |
Lung cancer in Berlin – Therapeutic concepts and their impact on survival in patients with NSCLC stage II/III from 2000 to 2008
T. Blum, S. Eggeling, C. Gogoll, C. Grah, C. Grohé, C. Lauer, G. Leschber, J. Neudecker, W. Pankow, B. Schicke, P. Schneider, N. Schoenfeld, C. Witt, A. Jagota (Berlin, Germany)
| |
Treatment modalities in lung cancer patients with brain metastasis
E. Budišin, N. Budisin, N. Lalic, D. Sazdanic, A. Andelkovic (Novi Sad, Sremska Kamenica, Republic Of Serbia)
| |
Prodromal face of a study: High dose rate endobronchial brachytherapy (HDERB) as a first step introductory treatment of a multimodality therapy approach in non operable NSCLC with endobronchial obstruction
K. Papalla, D. Bisirtzoglou, V. Anastasakos, A. Zetos, C. Marketos, I. Katsilieris, G. Politis (Athens, Greece)
| |
Non-small cell lung cancer – Advanced disease: Barriers to inclusion in clinical trials and its impact on survival
C. Lares dos Santos, L. Fernandes, I. Sanches, F. Cruz e Costa, F. Barata (Coimbra, Portugal)
| |
Intratumoral injection of plasmid-encoded flagellin inhibits growth of NSCLC-cells in murine lung cancer model
M. Jankowski, T. Wandtke, R. Lenartowski, O. Haus, P. Kopinski (Bydgoszcz, Torun, Poland)
| |